GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » PB Ratio
中文

Anika Therapeutics (Anika Therapeutics) PB Ratio : 1.79 (As of Apr. 24, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-24), Anika Therapeutics's share price is $25.90. Anika Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $14.48. Hence, Anika Therapeutics's PB Ratio of today is 1.79.

The historical rank and industry rank for Anika Therapeutics's PB Ratio or its related term are showing as below:

ANIK' s PB Ratio Range Over the Past 10 Years
Min: 0.93   Med: 2.38   Max: 4.56
Current: 1.79

During the past 13 years, Anika Therapeutics's highest PB Ratio was 4.56. The lowest was 0.93. And the median was 2.38.

ANIK's PB Ratio is ranked better than
58.54% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 2.21 vs ANIK: 1.79

During the past 12 months, Anika Therapeutics's average Book Value Per Share Growth Rate was -25.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -8.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -3.60% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 5.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Anika Therapeutics was 42.80% per year. The lowest was -24.60% per year. And the median was 11.50% per year.

Back to Basics: PB Ratio


Anika Therapeutics PB Ratio Historical Data

The historical data trend for Anika Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics PB Ratio Chart

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.57 2.38 1.80 1.52 1.57

Anika Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 1.53 1.39 1.01 1.57

Competitive Comparison of Anika Therapeutics's PB Ratio

For the Medical Instruments & Supplies subindustry, Anika Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anika Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's PB Ratio falls into.



Anika Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Anika Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=25.90/14.479
=1.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Anika Therapeutics  (NAS:ANIK) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Anika Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics (Anika Therapeutics) Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Anne Nunes officer: SVP, Chief Operations Officer 32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti director 600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran officer: EVP, General Counsel, Corp Sec 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz officer: EVP, CFO, Treasurer C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land director
Stephen Richard director C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop officer: EVP Business Development C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung officer: CFO ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen director 32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower director 32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson director 1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling officer: President 501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767